favicon-300x300

ERS Genomics

ERS is the world leader in licensing CRISPR/Cas9 technology for a wide variety of applications.
 
Our founder, Dr. Emmanuelle Charpentier (the ‘E’in ERS) won the Nobel Prize the discovery of CRISPR/Cas9 in 2020. 

Without question, CRISPR/Cas9 has transformed the field of gene editing. At ERS Genomics, our purpose is to extend global access to this technology and expand the boundaries of CRISPR potential.
 
 
 
 

 

BIO-Europe is the perfect time to start a conversation about your CRISPR license. We are excited to connect with companies who can benefit from this game-changing technology.
A meeting or a call with us is worthwhile for you if:

You are interested in possible use of CRISPR/Cas9 for internal research programs:
– Are you using modified cells or animals from an academic source?
– Are you generating in-house reagents?

 

You are interested in use of genetically modified cells in manufacturing. Including… 
– mAbs
– Gene or cell therapy
– Vectors
– Industrial enyzmes or intermediates

 

You provide any services which utilize CRISPR/Cas9 or cells or animals modified by the technology. Including…
– High-throughput screening 
– Target identification, Target validation
– Cell line development
– Disease specific cell models
– Animal models of disease

 

You have an interest in animal health applications. Including… 
– Disease resistance, Vaccines Trait improvements

 
 
Let’s schedule a meeting in Basel

Schedule time with Dr. Ralph Vogelsang, Senior Director, Business Development & Licensing, ERS Genomics

‘Your journey with CRISPR begins with a license from ERS Genomics. I am delighted to be back at BIO 2023. If you would like to learn more about CRISPR/Cas9 and licensing, connect with me and let’s talk.’

Schedule a Meeting
Bio Partnering

Licensing

Learn More

Intellectual Property

Learn More

Knowledge Centre

Learn More

Contact US

Learn More

Read More Of Our Articles

Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.

10 Years of ERS Genomics

Join us as we look back on a decade of ERS Genomics, CRISPR and the IP that made it possible. Over the past 10 years, CRISPR/Cas9 has moved from breakthrough discovery to a foundational platform for modern biology. In parallel, ERS Genomics has grown into the global leader in CRISPR/Cas9.

Read Full Article

ERS Genomics and Dyadic Applied BioSolutions Sign CRISPR/Cas9 License Agreement

License enables Dyadic Applied BioSolutions to expand genetic engineering capabilities Dublin, Ireland, and Jupiter FL, USA, 10 November 2025: ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions (‘Dyadic’), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced they have.

Read Full Article

CRISPR-GPT — The Future of Bioengineering

Merging CRISPR Gene Editing with Agentic AI   A new AI co-pilot automates genome engineering, accelerating discovery and democratizing CRISPR expertise.    Introduction: The Convergence of Two Powerful Technologies  Two of the most transformative technologies of our era, CRISPR/Cas9 gene editing and large language models (LLMs), are converging to reshape.

Read Full Article